Home » Stocks » VRDN

Viridian Therapeutics, Inc. (VRDN)

Stock Price: $17.53 USD 0.17 (0.98%)
Updated May 7, 2021 4:00 PM EDT - Market closed
After-hours: $17.55 +0.02 (0.11%) May 7, 5:10 PM
Market Cap 127.71M
Revenue (ttm) 1.67M
Net Income (ttm) -121.13M
Shares Out 6.34M
EPS (ttm) -31.49
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $17.53
Previous Close $17.36
Change ($) 0.17
Change (%) 0.98%
Day's Open 17.68
Day's Range 17.30 - 17.86
Day's Volume 5,476
52-Week Range 7.08 - 25.67

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

BOULDER, Colo., May 06, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underse...

1 day ago - GlobeNewsWire

BOULDER, Colo., March 25, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...

1 month ago - GlobeNewsWire

Viridian Therapeutics (NASDAQ:VRDN) releases its next round of earnings this Thursday, March 25. Here is Benzinga's essential guide to Viridian Therapeutics's Q4 earnings report.

1 month ago - Benzinga

Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

BOULDER, Colo., March 09, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but under...

1 month ago - GlobeNewsWire

Viridian Therapeutics, Inc. (VRDN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

BOULDER, Colo., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a development-stage biopharmaceutical company, today announced that Jonathan Violin, Ph.D., President and Ch...

2 months ago - GlobeNewsWire

With the trading day about half over, the broad markets had pulled back on Monday.

Other stocks mentioned: AAPL, GOOG, GOOGL, ROKU, TSLA, BBBY, CRWD ...
3 months ago - 24/7 Wall Street

BOULDER, Colo., Jan. 19, 2021 (GLOBE NEWSWIRE) -- miRagen Therapeutics, Inc. (NASDAQ: MGEN), a development-stage biotechnology company, today announced its name change to Viridian Therapeutics, Inc. (“V...

Other stocks mentioned: MGEN
3 months ago - GlobeNewsWire

About VRDN

Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody for the treatment of thyroid eye disease; VRDN-002, a biosuperior IGF-1R antibody; and VRDN-003, an IGF-1R antibody product specifically designed for thyroid eye disease. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is based in... [Read more...]

Industry
Biotechnology
Founded
2006
CEO
William Marshall
Employees
26
Stock Exchange
NASDAQ
Ticker Symbol
VRDN
Full Company Profile

Financial Performance

In 2020, VRDN's revenue was $1.05 million, a decrease of -76.46% compared to the previous year's $4.46 million. Losses were -$110.72 million, 164.4% more than in 2019.

Financial Statements